The prostate cancer bone marrow niche: More than just fertile soil

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 423-427

  Pedersen, Elisabeth A ^a   Shiozawa, Yusuke ^a   Pienta, Kenneth J ^b   Taichman, Russell S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

dormancy; hematopoietic stem cell; metastasis; niche; osteoblasts; prostate cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1;

BONE MARROW; CANCER GROWTH; CELL ACTIVITY; CELL INTERACTION; HEMATOPOIETIC STEM CELL; HUMAN; METASTASIS; OSTEOBLAST; PROSTATE CANCER; PROTEIN LOCALIZATION; REVIEW; STEM CELL NICHE; TARGET CELL; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BONE MARROW NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; OSTEOBLASTS; PROSTATIC NEOPLASMS;

EID: 84860851484     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.164     Document Type: Review

References (68)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
2. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: Habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22: 941-950. (Pubitemid 351689875)
3. Taichman RS. Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005; 105: 2631-2639. (Pubitemid 40446251)
4. Yin T, Li L. The stem cell niches in bone. J Clin Invest 2006; 116: 1195-1201.
5. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008; 8: 290-301. (Pubitemid 351432804)
6. Nakamura Y, Arai F, Iwasaki H, Hosokawa K, Kobayashi I et al. Isolation and characterization of endosteal niche cell populations that regulate hematopoietic stem cells. Blood 2010; 116: 1422-1432.
7. Doan PL, Chute JP. The vascular niche: Home for normal and malignant hematopoietic stem cells. Leukemia; e-pub ahead of print 2 September 2011; doi: 10.1038/leu.2011.236.
8. Arai F, Yoshihara H, Hosokawa K, Nakamura Y, Gomei Y et al. Niche regulation of hematopoietic stem cells in the endosteum. Ann NY Acad Sci 2009; 1176: 36-46.
9. Kiel MJ, Acar M, Radice GL, Morrison SJ. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell 2009; 4: 170-179.
10. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
11. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-846. (Pubitemid 350006258)
12. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y et al. A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index. Clin Cancer Res 1998; 4: 1765-1772. (Pubitemid 28304740)
13. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146: 1727-1736. (Pubitemid 40396881)
14. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH et al. Detection and isolation of prostate cancer cells fromperipheral blood and bone marrow. Urology 2003; 61: 277-281. (Pubitemid 36206516)
15. Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007; 12: 3000-3009.
16. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-689. (Pubitemid 35232337)
17. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: Defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 2008; 1: 158-164.
18. Neiva K, Sun YX, Taichman RS. The role of osteoblasts in regulating hematopoietic stem cell activity and tumor metastasis. Braz J Med Biol Res 2005; 38: 1449-1454. (Pubitemid 41440216)
19. Jung Y, Wang J, Havens A, Sun Y, Jin T et al. Cell-To-cell contact is critical for the survival of hematopoietic progenitor cells on osteoblasts. Cytokine 2005; 32: 155-162. (Pubitemid 41681789)
20. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846. (Pubitemid 37351468)
21. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK et al. Prostate carcinoma skeletal metastases: Cross-Talk between tumor and bone. Cancer Metastasis Rev 2001; 20: 333-349. (Pubitemid 34595275)
22. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121: 1298-1312.
23. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y et al. Anin vivo mouse model for human prostate cancer metastasis. Neoplasia 2008; 10: 371-380.
24. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837. (Pubitemid 34408510)
25. Sun YX, Schneider A, Jung Y, Wang J, Dai J et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318-329.
26. Sun YX, Wang J, Shelburne CE, Lopatin DE, ChinnaiyanAMet al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89: 462-473. (Pubitemid 36648768)
27. Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283-4294.
28. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ et al. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007; 67: 61-73. (Pubitemid 46013468)
29. Havens AM, Jung Y, Sun YX, Wang J, Shah RB et al. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer 2006; 6: 195.
30. Sun YX, Pedersen EA, Shiozawa Y, Havens AM, Jung Y et al. CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 2008; 25: 765-776.
31. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD341 hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD341 progenitors to peripheral blood. J Exp Med 1997; 185: 111-120. (Pubitemid 27039446)
32. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T et al. Dependence of human stem cell engraftment and repopulation of NOD/SCIDmice on CXCR4. Science 1999; 283: 845-848.
33. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000; 106: 1331-1339.
34. Aiuti A, Tavian M, Cipponi A, Ficara F, Zappone E et al. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lymphohematopoietic progenitors. Eur J Immunol 1999; 29: 1823-1831. (Pubitemid 29265537)
35. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638. (Pubitemid 26268957)
36. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006; 5: 1744-1750. (Pubitemid 44435316)
37. Pedersen EA, Shiozawa Y, Taichman RS. Structure and function of the solid tumor niche. Front Biosci. In Press
38. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161. (Pubitemid 38962572)
39. Jung Y, Wang J, Song J, Shiozawa Y, Havens A et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 2007; 110: 82-90. (Pubitemid 47026822)
40. Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 2008; 105: 370-380.
41. Mai J, Waisman DM, Sloane BF. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 2000; 1477: 215-230. (Pubitemid 30119902)
42. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 2010; 12: 116-127.
43. Dormady SP, Zhang XM, Basch RS. Hematopoietic progenitor cells grow on 3T3 fibroblast monolayers that overexpress growth arrest-specific gene-6 (GAS6). Proc Natl Acad Sci USA 2000; 97: 12260-5.
44. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994; 84: 1931-1941. (Pubitemid 24286145)
45. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2012; 15: 677-683.
46. Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, KleinJR et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007; 25: 214-220. (Pubitemid 46670754)
47. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990; 322: 605-612. (Pubitemid 20190796)
48. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21: 337-344. (Pubitemid 13161851)
49. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL et al. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008; 180: 1154-1160.
50. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177: 17-24. (Pubitemid 44879461)
51. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660. (Pubitemid 36749213)
52. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-514.
53. Jung Y, Shiozawa Y, Wang J, Wang Z, Pedersen EA et al. Expression of PGK1 by prostate cancer cells induces bone formation. Mol Cancer Res 2009; 7: 1595-1604.
54. Jung Y, Song J, Shiozawa Y, Wang J, Wang Z et al. Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells 2008; 26: 2042-2051.
55. Joseph J, Shiozawa Y, Jung Y, Kim JK, Pedersen E, Mishra A, Zalucia JL, Wang J, Keller ET, Pienta KJ, Taichman RS. Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res 2012 Jan 12 [Epub ahead of print].
56. Spivak JL. Cancer-related anemia: Its causes and characteristics. Semin Oncol 1994; 21: (2 Suppl 3): 3-8. (Pubitemid 24172363)
57. Eriksson S, Killander J, Wadman B. Leuco-erythroblastic anaemia in prostatic cancer. Report of two cases with complete haematological remission. Scand J Haematol 1972; 9: 648-653.
58. Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71: 3594-3600. (Pubitemid 23152670)
59. Abkowitz JL, Robinson AE, Kale S, LongMW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003; 102: 1249-1253. (Pubitemid 36988029)
60. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K et al. Augmented mobilization and collection of CD341 hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300. (Pubitemid 40389423)
61. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874. (Pubitemid 41208607)
62. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318. (Pubitemid 40629073)
63. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694. (Pubitemid 34752479)
64. Hatse S, Princen K, Bridger G, de Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527: 255-262. (Pubitemid 35253875)
65. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
66. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
67. Jung Y, Shiozawa Y, Wang J, Patel LR, Havens AM et al. Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol 2011; 39: 151-66.e1.
68. Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011; 17: 5553-5558.